comprehensive -WSS

comprehensive

author：hotspot 2025-08-11 07:59:10 - browse：341

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Researchers tackle phage therapy hurdles for wider adoption

WSS

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Abridge raises $150m as clinical notes automation market heats up

Opioid cravings were reduced by anti

Secretariat’s lessons for human medicine

Medicare Advantage enrollment hits roughly 33.4 million

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Wikipedia

comprehensive

explore

Heart attack and stroke risk calculators need revising

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Dobbs anniversary: the lost opportunity of abortion as health care

How doctors’ personal politics affect patients

Medicare proposal to cover medical devices draws a mixed reaction

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Guidelines to prevent youth baseball injuries need more muscle

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

Opioid cravings were reduced by anti

Roche’s Alnylam deal shows drug firms interested in heart drugs

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Why patients can’t get everything they want on drug pricing

focus

hotspot

entertainment

hotspot